03.01.11
Netherlands-based Royal DSM N.V. has acquired Martek Biosciences Corporation, Columbia, MD, for more than $1 billion. Martek will provide DSM with new opportunities in the infant nutrition segment as well as food and beverage and dietary supplements and create a strong platform for DSM to enter the growing omega 3 and omega 6 market through Martek’s microbial DHA (docosahexaenoic acid) and ARA (arachidonic acid) products. DSM will be able to channel and accelerate the growth of these products into other regions, applications and market segments beyond Martek’s current U.S.-based position in infant formula ingredients and growing position in food and beverage and dietary supplement applications.
The two companies already have a longstanding relationship, as DSM supplies Martek with the key base material for its ARA product. DSM has complementary intellectual property to the broad range of patents and intellectual property Martek owns, which will further extend the competitiveness of the combined company’s proprietary products. DSM will also benefit from Martek’s recent acquisition of Amerifit, a consumer business for branded dietary supplements with specific health benefits. The acquisition is expected to realize material revenue synergies through expanded distribution, marketing and product development as well as other operational efficiencies, and will accelerate DSM’s revenue growth.
The two companies already have a longstanding relationship, as DSM supplies Martek with the key base material for its ARA product. DSM has complementary intellectual property to the broad range of patents and intellectual property Martek owns, which will further extend the competitiveness of the combined company’s proprietary products. DSM will also benefit from Martek’s recent acquisition of Amerifit, a consumer business for branded dietary supplements with specific health benefits. The acquisition is expected to realize material revenue synergies through expanded distribution, marketing and product development as well as other operational efficiencies, and will accelerate DSM’s revenue growth.